应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
LLY 礼来
耶稣受难日休市 03-28 16:00:00 EDT
777.96
-0.22
-0.03%
盘后
776.50
-1.46
-0.19%
19:59 EDT
最高
793.67
最低
776.44
成交量
320.94万
今开
780.32
昨收
778.18
日振幅
2.21%
总市值
7,397亿
流通市值
7,375亿
总股本
9.51亿
成交额
25.17亿
换手率
0.34%
流通股本
9.48亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
媒体-Rite Aid、亚马逊药店证实礼来的 Zepbound 供不应求--彭博新闻社
Reuters · 00:10
媒体-Rite Aid、亚马逊药店证实礼来的 Zepbound 供不应求--彭博新闻社
据悉亚马逊依靠减肥狂潮来提振药房业务
老虎智能写手 · 03-27 09:52
据悉亚马逊依靠减肥狂潮来提振药房业务
美国食品药品管理局(FDA):减肥药针剂Zepbound(礼来制药生产的替尔泊肽)供应充足
华尔街见闻 · 03-27 08:16
美国食品药品管理局(FDA):减肥药针剂Zepbound(礼来制药生产的替尔泊肽)供应充足
把握黄金窗口期,开启阿尔茨海默病管理新范式——礼来制药董事长兼首席执行官戴文睿出席国际医药创新大会
新浪医药 · 03-25
把握黄金窗口期,开启阿尔茨海默病管理新范式——礼来制药董事长兼首席执行官戴文睿出席国际医药创新大会
更新版 1-欧盟药品监管机构未在会议记录中提及卫材-百健的阿尔茨海默氏症药物
Reuters · 03-22
更新版 1-欧盟药品监管机构未在会议记录中提及卫材-百健的阿尔茨海默氏症药物
德国公共卫生机构在韦戈维保险覆盖范围方面发出宽松信号
Reuters · 03-22
德国公共卫生机构在韦戈维保险覆盖范围方面发出宽松信号
隔夜美股全复盘(3.21)| 三大股指集体收涨,美联储暗示今年降息幅度不下调;美光盘后涨逾17%,上季营收超预期增近60%,本季指引再度碾压预期
格隆汇 · 03-21
隔夜美股全复盘(3.21)| 三大股指集体收涨,美联储暗示今年降息幅度不下调;美光盘后涨逾17%,上季营收超预期增近60%,本季指引再度碾压预期
诺和诺德与礼来“闪跌”,国会机构警告减肥药恐推升美国赤字
华尔街见闻 · 03-21
诺和诺德与礼来“闪跌”,国会机构警告减肥药恐推升美国赤字
诺和诺德与礼来跌幅扩大,国会山谈及减肥药对美国赤字的不利影响
华尔街见闻 · 03-21
诺和诺德与礼来跌幅扩大,国会山谈及减肥药对美国赤字的不利影响
礼来上涨1.22%,报772.0美元/股
金融界 · 03-20
礼来上涨1.22%,报772.0美元/股
摩根大通:礼来管理层认为口服药将改变格局,“减肥双雄”护城河被市场低估
华尔街见闻 · 03-19
摩根大通:礼来管理层认为口服药将改变格局,“减肥双雄”护城河被市场低估
礼来上涨1.24%,报763.51美元/股
金融界 · 03-18
礼来上涨1.24%,报763.51美元/股
NASH药物市场预计到2035年将超过480亿美元 诺和诺德(NVO.US)和礼来(LLY.US)等公司开始布局
智通财经 · 03-18
NASH药物市场预计到2035年将超过480亿美元 诺和诺德(NVO.US)和礼来(LLY.US)等公司开始布局
礼来减肥药 Zepbound 在美国的新处方首次超过威戈维
Reuters · 03-16
礼来减肥药 Zepbound 在美国的新处方首次超过威戈维
资料盒-Madrigal公司的药物在美国首次获批治疗脂肪肝NASH,竞争对手却围追堵截
Reuters · 03-15
资料盒-Madrigal公司的药物在美国首次获批治疗脂肪肝NASH,竞争对手却围追堵截
BUZZ-穆迪称因GLP-1药物推动制药业前景转为 "积极
Reuters · 03-14
BUZZ-穆迪称因GLP-1药物推动制药业前景转为 "积极
礼来联手亚马逊扩大直销网络,Zepbound销售额预计2024年达22亿
和讯网 · 03-14
礼来联手亚马逊扩大直销网络,Zepbound销售额预计2024年达22亿
礼来将与亚马逊合作提供处方药配送服务
金融界 · 03-13
礼来将与亚马逊合作提供处方药配送服务
强强联合! 礼来(LLY.US)将携手亚马逊(AMZN.US)合作配送“减肥神药”
智通财经 · 03-13
强强联合! 礼来(LLY.US)将携手亚马逊(AMZN.US)合作配送“减肥神药”
BUZZ-礼来选择亚马逊配送 Zepbound 和其他药物后,沃尔格林下跌
Reuters · 03-13
BUZZ-礼来选择亚马逊配送 Zepbound 和其他药物后,沃尔格林下跌
公司概况
公司名称:
礼来
所属市场:
NYSE
上市日期:
--
主营业务:
礼来公司于1901年在印第安纳州注册成立,其前身是1876年由伊利·礼来上校在印第安纳州印第安纳波利斯创立的药品生产企业。公司发现,开发,制造和销售重要医药产品。公司的宗旨是将“关爱”与“发现”结合起来,为世界各地的人们创造更美好的生活。
发行价格:
--
{"stockData":{"symbol":"LLY","market":"US","secType":"STK","nameCN":"礼来","latestPrice":777.96,"timestamp":1711656000000,"preClose":778.18,"halted":0,"volume":3209424,"hourTrading":{"tag":"盘后","latestPrice":776.5,"preClose":777.96,"latestTime":"19:59 EDT","volume":273640,"amount":212874195.3347,"timestamp":1711670362886},"delay":0,"floatShares":948000000,"shares":950766100,"eps":5.521359,"marketStatus":"耶稣受难日休市","marketStatusCode":7,"change":-0.22,"latestTime":"03-28 16:00:00 EDT","open":780.32,"high":793.67,"low":776.44,"amount":2516770284.5712,"amplitude":0.022141,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":5.521359,"exchange":"NYSE","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1711958400000},"adr":0,"listingDate":102488400000,"adjPreClose":778.18,"adrRate":0,"dividendRate":0.00581,"preHourTrading":{"tag":"盘前","latestPrice":779.16,"preClose":778.18,"latestTime":"09:28 EDT","volume":3049,"amount":2371555.1909000003,"timestamp":1711632501911},"postHourTrading":{"tag":"盘后","latestPrice":776.5,"preClose":777.96,"latestTime":"19:59 EDT","volume":273640,"amount":212874195.3347,"timestamp":1711670362886},"volumeRatio":1.4331603930805301},"requestUrl":"/m/hq/s/LLY/wiki","defaultTab":"wiki","newsList":[{"id":"2423112443","title":"媒体-Rite Aid、亚马逊药店证实礼来的 Zepbound 供不应求--彭博新闻社","url":"https://stock-news.laohu8.com/highlight/detail?id=2423112443","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2423112443?lang=zh_cn&edition=full","pubTime":"2024-03-29 00:10","pubTimestamp":1711642248,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) 3月28日 - -- 来源链接: -- 注:路透社未核实此报道,不保证其准确性","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"1115079041","title":"据悉亚马逊依靠减肥狂潮来提振药房业务","url":"https://stock-news.laohu8.com/highlight/detail?id=1115079041","media":"老虎智能写手","top":-1,"share":"https://www.laohu8.com/m/news/1115079041?lang=zh_cn&edition=full","pubTime":"2024-03-27 09:52","pubTimestamp":1711504357,"startTime":"0","endTime":"0","summary":"报道称,此前与亚马逊药房业务负责人约翰·洛夫进行的采访透露了这一消息。洛夫表示,尽管存在供应约束,但亚马逊药房已经为患者提供了这两种 GLP-1 激动剂,这些药物有望为该部门带来“大量收入”。洛夫指出,虽然亚马逊并未对其药房业务的销售额进行细分,“但我们看到了快速增长……我预计这种增长会持续下去。”在与伊利莱合作提供一些处方药的家庭送货服务数周后,洛夫发表了上述言论,其中包括 Zepbound。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"gpt_icon":0},{"id":"2422603022","title":"美国食品药品管理局(FDA):减肥药针剂Zepbound(礼来制药生产的替尔泊肽)供应充足","url":"https://stock-news.laohu8.com/highlight/detail?id=2422603022","media":"华尔街见闻","top":-1,"share":"https://www.laohu8.com/m/news/2422603022?lang=zh_cn&edition=full","pubTime":"2024-03-27 08:16","pubTimestamp":1711498570,"startTime":"0","endTime":"0","summary":"美国食品药品管理局(FDA):减肥药针剂Zepbound( 礼来 制药生产的替尔泊肽)供应充足。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403270827248b674e86&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403270827248b674e86&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422563804","title":"把握黄金窗口期,开启阿尔茨海默病管理新范式——礼来制药董事长兼首席执行官戴文睿出席国际医药创新大会","url":"https://stock-news.laohu8.com/highlight/detail?id=2422563804","media":"新浪医药","top":-1,"share":"https://www.laohu8.com/m/news/2422563804?lang=zh_cn&edition=full","pubTime":"2024-03-25 15:02","pubTimestamp":1711350165,"startTime":"0","endTime":"0","summary":"礼来制药董事长兼首席执行官戴文睿先生受邀参会,并在“医药创新助力实现健康中国2030目标”全球CEO圆桌讨论中,围绕“推进中国阿尔茨海默病创新诊疗路径”发表了其观点洞见,强调了随着阿尔茨海默病突破性疗法的创新,其配套医疗管理系统向疾病早期阶段转移的重要性。与此同时,礼来积极与各方协作,推进完善AD诊疗路径、提升大众对于疾病的认知。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403251503238b5ff3ab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403251503238b5ff3ab&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2421575896","title":"更新版 1-欧盟药品监管机构未在会议记录中提及卫材-百健的阿尔茨海默氏症药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2421575896","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2421575896?lang=zh_cn&edition=full","pubTime":"2024-03-22 19:05","pubTimestamp":1711105550,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) (添加背景信息) 路透社3月22日 - 欧盟药品监管机构周五在其说明和建议中没有提及卫材 和百健 的阿尔茨海默氏症药物。 欧洲药品管理局曾表示将在本周举行口头听证会,讨论这种名为lecanemab的药物。 该药在美国以Leqembi的名义销售,自2023年1月起在欧洲接受审查。该药去年在美国获得传统批准,并在中国和日本等其他国家获得批准。 这种药物每月输注两次,可以清除大脑中被认为是阿尔茨海默氏症标志的淀粉样β蛋白的粘性团块。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2421862607","title":"德国公共卫生机构在韦戈维保险覆盖范围方面发出宽松信号","url":"https://stock-news.laohu8.com/highlight/detail?id=2421862607","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2421862607?lang=zh_cn&edition=full","pubTime":"2024-03-22 17:38","pubTimestamp":1711100301,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) 路透社法兰克福3月22日 - 德国一家重要的药品报销机构表示,禁止 (link),德国的医疗保险系统将不支付Wegovy等减肥药的费用,这一规定不适用于每周注射一次的减肥药的其他批准用途。周四晚些时候,欧洲最大的国家药品市场卫生机构G-BA在网上公布了这一指导意见,这是药品制造商诺和诺德 通过展示减肥以外的健康益处来扩大欧洲保险覆盖面的初步迹象之一。欧盟药品监管机构 (link),该机构一直在审查广受欢迎的Wegovy的更广泛用途,包括降低中风和心脏病发作的风险,以及之前获批的用于解决肥胖问题的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2421089513","title":"隔夜美股全复盘(3.21)| 三大股指集体收涨,美联储暗示今年降息幅度不下调;美光盘后涨逾17%,上季营收超预期增近60%,本季指引再度碾压预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2421089513","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2421089513?lang=zh_cn&edition=full","pubTime":"2024-03-21 07:59","pubTimestamp":1710979162,"startTime":"0","endTime":"0","summary":"三大股指集体收涨,美联储暗示今年降息幅度不下调;美光盘后涨逾17%,上季营收超预期增近60%,本季指引再度碾压预期","market":"hk","thumbnail":"https://img7.gelonghui.com/column/2/140.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/140.png"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/709821","is_publish_highlight":false,"gpt_icon":0},{"id":"1147908226","title":"诺和诺德与礼来“闪跌”,国会机构警告减肥药恐推升美国赤字","url":"https://stock-news.laohu8.com/highlight/detail?id=1147908226","media":"华尔街见闻","top":-1,"share":"https://www.laohu8.com/m/news/1147908226?lang=zh_cn&edition=full","pubTime":"2024-03-21 01:42","pubTimestamp":1710956546,"startTime":"0","endTime":"0","summary":"礼来和诺和诺德美股盘中跌幅迅速扩大、刷新日低,分别跌超2%和近2%。更新中美国国会下设无党派机构国会预算办公室警告减肥药带给美国政府赤字的负面影响。CBO的分析师称,减肥药给美国造成的成本将超过预估的结余。如果将减肥药纳入医保,将推升美国未来十年的赤字。礼来刷新日低时日内跌近2.1%,在美上市的诺和诺德美股刷新日低时日内跌逾1.9%,后跌幅均明显收窄。","market":"us","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3710936","is_publish_highlight":true,"gpt_icon":1},{"id":"2421720836","title":"诺和诺德与礼来跌幅扩大,国会山谈及减肥药对美国赤字的不利影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2421720836","media":"华尔街见闻","top":-1,"share":"https://www.laohu8.com/m/news/2421720836?lang=zh_cn&edition=full","pubTime":"2024-03-21 00:11","pubTimestamp":1710951112,"startTime":"0","endTime":"0","summary":"美国国会预算管理办公室(CBO)分析师称,减肥药给美国造成的成本将超过预估的结余。 如果将减肥药纳入...","market":"hk","thumbnail":"https://wpimg-wscn.awtmt.com/d0/24/94/-1-2-.png","type":0,"news_type":0,"thumbnails":["https://wpimg-wscn.awtmt.com/d0/24/94/-1-2-.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3710936","is_publish_highlight":false,"gpt_icon":0},{"id":"2420098272","title":"礼来上涨1.22%,报772.0美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2420098272","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2420098272?lang=zh_cn&edition=full","pubTime":"2024-03-20 02:09","pubTimestamp":1710871747,"startTime":"0","endTime":"0","summary":"3月20日,礼来(LLY)盘中上涨1.22%,截至02:09,报772.0美元/股,成交9.44亿美元。财务数据显示,截至2023年12月31日,礼来收入总额341.24亿美元,同比增长19.56%;归母净利润52.4亿美元,同比减少16.08%。大事提醒:4月25日,礼来将披露2024财年一季报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/03/20020939911879.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2420428602","title":"摩根大通:礼来管理层认为口服药将改变格局,“减肥双雄”护城河被市场低估","url":"https://stock-news.laohu8.com/highlight/detail?id=2420428602","media":"华尔街见闻","top":-1,"share":"https://www.laohu8.com/m/news/2420428602?lang=zh_cn&edition=full","pubTime":"2024-03-19 02:41","pubTimestamp":1710787306,"startTime":"0","endTime":"0","summary":"摩根大通认为,得益于“减肥双雄”礼来和诺和诺德的强大研发能力、盈利能力、烧钱能力,它们的护城河较宽,持续赚钱的概率非常大。且礼来新型orforglipron口服药物将改变减肥及糖尿病药物市场格局。","market":"us","thumbnail":"https://static.tigerbbs.com/81e27145dc6f57555c991db0a7bb21e8","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/81e27145dc6f57555c991db0a7bb21e8"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3710744","is_publish_highlight":true,"gpt_icon":1},{"id":"2420470722","title":"礼来上涨1.24%,报763.51美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2420470722","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2420470722?lang=zh_cn&edition=full","pubTime":"2024-03-18 22:10","pubTimestamp":1710771032,"startTime":"0","endTime":"0","summary":"3月18日,礼来(LLY)盘中上涨1.24%,截至22:10,报763.51美元/股,成交2.38亿美元。财务数据显示,截至2023年12月31日,礼来收入总额341.24亿美元,同比增长19.56%;归母净利润52.4亿美元,同比减少16.08%。大事提醒:4月25日,礼来将披露2024财年一季报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/03/18221039893341.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2420346498","title":"NASH药物市场预计到2035年将超过480亿美元 诺和诺德(NVO.US)和礼来(LLY.US)等公司开始布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2420346498","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2420346498?lang=zh_cn&edition=full","pubTime":"2024-03-18 09:00","pubTimestamp":1710723600,"startTime":"0","endTime":"0","summary":"然而,受地区肥胖率上升的推动,预计欧洲NASH治疗市场的年复合增长率最高,为18.6%。与此同时,今年1月,医疗保健分析公司IQVIA表示,到2030年,NASH治疗的全球市场规模将超过1000亿美元。IQV指的是低诊出率和监管部门批准所需的严格临床试验要求等因素。其中值得注意的是由诺和诺德开发的减肥疗法semaglutide。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1087544.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2419618895","title":"礼来减肥药 Zepbound 在美国的新处方首次超过威戈维","url":"https://stock-news.laohu8.com/highlight/detail?id=2419618895","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2419618895?lang=zh_cn&edition=full","pubTime":"2024-03-16 01:38","pubTimestamp":1710524330,"startTime":"0","endTime":"0","summary":" Patrick Wingrove 路透社3月15日 - 根据IQVIA的数据,礼来 的强效减肥药Zepbound在截至3月8日的一周内新增处方77590张,自上市以来首次超过了诺和诺德 的竞争对手肥胖药Wegovy。据 GlobalData 预测,到 2029 年,礼来的糖尿病药物 Mounjaro将成为最畅销的 GLP-1 药物,年销售额将达到 334 亿美元。礼来公司本周表示,它已与亚马逊公司 的药房部门合作,向其直接面向消费者的服务LillyDirect发送药品处方 ,其中包括Zepbound的处方。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2419124937","title":"资料盒-Madrigal公司的药物在美国首次获批治疗脂肪肝NASH,竞争对手却围追堵截","url":"https://stock-news.laohu8.com/highlight/detail?id=2419124937","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2419124937?lang=zh_cn&edition=full","pubTime":"2024-03-15 04:09","pubTimestamp":1710446976,"startTime":"0","endTime":"0","summary":" 路透社3月14日 - Madrigal Pharmaceuticals公司的 药物成为第一个获得监管部门批准的 ,用于治疗一种以前被称为非酒精性脂肪性肝炎的严重类型的脂肪肝,因为开发一个数十亿美元市场的竞争正在加剧。在周四获得批准之前,该公司在开发这种疾病的治疗方法方面取得了有限的成功,这种疾病与肥胖密切相关,而且正在迅速蔓延。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2419983375","title":"BUZZ-穆迪称因GLP-1药物推动制药业前景转为 \"积极","url":"https://stock-news.laohu8.com/highlight/detail?id=2419983375","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2419983375?lang=zh_cn&edition=full","pubTime":"2024-03-14 22:35","pubTimestamp":1710426957,"startTime":"0","endTime":"0","summary":" 3月14日 - ** 穆迪评级公司称,GLP-1 和其他大片药物已将美国制药业信贷展望从 \"稳定 \"提升至 \"积极\"。** 评级机构表示,该行业的增长将受益于大片药物使用量的增加,包括诺和诺德 和礼来 的GLP-1糖尿病和减肥治疗药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2419766749","title":"礼来联手亚马逊扩大直销网络,Zepbound销售额预计2024年达22亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2419766749","media":"和讯网","top":-1,"share":"https://www.laohu8.com/m/news/2419766749?lang=zh_cn&edition=full","pubTime":"2024-03-14 07:21","pubTimestamp":1710372108,"startTime":"0","endTime":"0","summary":"美国制药公司礼来宣布,已与亚马逊建立合作伙伴关系,通过亚马逊旗下药房部门为其线上服务平台LiLLYDirect Pharmacy Solutions提供处方药配送服务。礼来此前推出LillyDirect,让患者能够在线购买偏头痛、糖尿病和减肥药物,包括被称为“减肥神药”的Zepbound。礼来表示,将根据患者的保险覆盖范围和其他因素,通过亚马逊药房或Truepill进行快速配送。摩根士丹利预计,到2024年,Zepbound的销售额将达到22亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403140725208b2fe862&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403140725208b2fe862&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2419681570","title":"礼来将与亚马逊合作提供处方药配送服务","url":"https://stock-news.laohu8.com/highlight/detail?id=2419681570","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2419681570?lang=zh_cn&edition=full","pubTime":"2024-03-13 21:12","pubTimestamp":1710335521,"startTime":"0","endTime":"0","summary":"礼来表示,已经与亚马逊达成合作,亚马逊旗下药房部门将为其直接面向消费者的线上服务平台LiLLYDirect Pharmacy Solutions提供处方药配送服务。今年1月,礼来公司推出了这个直接面向消费者的线上服务平台,让患者可以通过线上药店Truepill直接从礼来获得偏头痛、糖尿病治疗药物以及用于减肥的药物,包括“减肥神药”Zepbound。礼来表示,发送给LillyDirect Pharmacy Solutions的处方现在将由亚马逊药房或者Truepill进行快速配送,具体取决于患者的保险覆盖范围和其他的影响因素。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240313211556877ca3c0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240313211556877ca3c0&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2419868525","title":"强强联合! 礼来(LLY.US)将携手亚马逊(AMZN.US)合作配送“减肥神药”","url":"https://stock-news.laohu8.com/highlight/detail?id=2419868525","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2419868525?lang=zh_cn&edition=full","pubTime":"2024-03-13 20:33","pubTimestamp":1710333180,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,美国医药巨头礼来当地时间周三表示,已经与亚马逊达成合作,亚马逊旗下药房部门将为其直接面向消费者的线上服务平台LillyDirect Pharmacy Solutions提供处方药配送服务。礼来表示,发送给LillyDirect Pharmacy Solutions的处方现在将由亚马逊药房或者Truepill进行快速配送,具体取决于患者的保险覆盖范围和其他的影响因素。在一年期的标记点,接受Tirzepatide治疗的患者的平均体重减少了15.2%,而Wegovy对照组则为7.9%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1086090.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2419387683","title":"BUZZ-礼来选择亚马逊配送 Zepbound 和其他药物后,沃尔格林下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2419387683","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2419387683?lang=zh_cn&edition=full","pubTime":"2024-03-13 19:56","pubTimestamp":1710330987,"startTime":"0","endTime":"0","summary":" 3月13日 - ** 美国连锁药店运营商沃尔格林博姿联盟 股价盘前下跌1.13%至21.04美元** 礼来公司 与亚马逊公司 的药房部门合作 ,向其直接面向消费者的网站LillyDirect提供处方药。** 礼来公司于1月份推出了LillyDirect ,使患者能够通过网上药店Truepill直接从该公司获得偏头痛、糖尿病和肥胖症药物,包括流行的减肥药Zepbound。** 根据患者的保险范围和其他因素,发送到 LillyDirect Pharmacy Solutions 的处方药现在将由亚马逊药房或 Truepill 配送。** 截至上一交易日收盘,WBA 的股价年累计下跌约 19","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.lilly.com","stockEarnings":[{"period":"1week","weight":0.01},{"period":"1month","weight":0.0169},{"period":"3month","weight":0.3346},{"period":"6month","weight":0.4484},{"period":"1year","weight":1.3163},{"period":"ytd","weight":0.3346}],"compareEarnings":[{"period":"1week","weight":0.0017},{"period":"1month","weight":0.0318},{"period":"3month","weight":0.1005},{"period":"6month","weight":0.2236},{"period":"1year","weight":0.3033},{"period":"ytd","weight":0.1005}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"礼来公司于1901年在印第安纳州注册成立,其前身是1876年由伊利·礼来上校在印第安纳州印第安纳波利斯创立的药品生产企业。公司发现,开发,制造和销售重要医药产品。公司的宗旨是将“关爱”与“发现”结合起来,为世界各地的人们创造更美好的生活。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.011498},{"month":2,"riseRate":0.5,"avgChangeRate":-0.002909},{"month":3,"riseRate":0.613636,"avgChangeRate":0.015389},{"month":4,"riseRate":0.545455,"avgChangeRate":0.019052},{"month":5,"riseRate":0.409091,"avgChangeRate":0.014113},{"month":6,"riseRate":0.590909,"avgChangeRate":0.021126},{"month":7,"riseRate":0.568182,"avgChangeRate":0.002184},{"month":8,"riseRate":0.409091,"avgChangeRate":0.00001},{"month":9,"riseRate":0.454545,"avgChangeRate":0.003204},{"month":10,"riseRate":0.590909,"avgChangeRate":0.014439},{"month":11,"riseRate":0.75,"avgChangeRate":0.027866},{"month":12,"riseRate":0.590909,"avgChangeRate":0.031834}],"exchange":"NYSE","name":"礼来","nameEN":"Eli Lilly"},"APP":{"userAgent":"claudebot","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.3","shortVersion":"4.22.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"礼来(LLY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供礼来(LLY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"礼来,LLY,礼来股票,礼来股票老虎,礼来股票老虎国际,礼来行情,礼来股票行情,礼来股价,礼来股市,礼来股票价格,礼来股票交易,礼来股票购买,礼来股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"礼来(LLY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供礼来(LLY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}